Schizophrenia Spectrum and Other Psychotic Disorders — Metacognitive Training and Insight in Schizophrenia
Citation(s)
Kemp R, David AS. Insight and Compliance. In: Blackwell, B editor. Treatment Compliance and the Therapeutic Alliance in Serious Mental Illness. The Netherlands: Harwood Academic Publishers; 1997. p. 61-86
Amador XF, David AS Insight and Psychosis. Awareness of Illness in Schizophrenia and Related Disorders. 2nd ed. New York: Oxford University Press; 2004.
Corcoran R, Mercer G, Frith CD Schizophrenia, symptomatology and social inference: investigating "theory of mind" in people with schizophrenia. Schizophr Res. 1995 Sep;17(1):5-13.
Cox D Regression models and life tables (with discussions). J R Stat Soc. 1972;34:187-220.
Cuesta MJ, Peralta V, Campos MS, Garcia-Jalon E Can insight be predicted in first-episode psychosis patients? A longitudinal and hierarchical analysis of predictors in a drug-naïve sample. Schizophr Res. 2011 Aug;130(1-3):148-56. doi: 10.1016/j.schres.2011.04.032. Epub 2011 May 31.
David AS Insight and psychosis. Br J Psychiatry. 1990 Jun;156:798-808. Review.
Eichner C, Berna F Acceptance and Efficacy of Metacognitive Training (MCT) on Positive Symptoms and Delusions in Patients With Schizophrenia: A Meta-analysis Taking Into Account Important Moderators. Schizophr Bull. 2016 Jul;42(4):952-62. doi: 10.1093/schbul/sbv225. Epub 2016 Jan 8.
Endicott J, Spitzer RL, Fleiss JL, Cohen J The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976 Jun;33(6):766-71.
Flavell JH Metacognition and cognitive monitoring: a new area of cognitive-developmental inquiry. Am Psychol. 1979;34:906-911
Gil D, Fernández-Modamio M, Bengochea R, Arrieta M [Adaptation of the Hinting Task theory of the mind test to Spanish]. Rev Psiquiatr Salud Ment. 2012 Apr-Jun;5(2):79-88. doi: 10.1016/j.rpsm.2011.11.004. Epub 2012 Jan 20. Spanish.
Insel TR Digital Phenotyping: Technology for a New Science of Behavior. JAMA. 2017 Oct 3;318(13):1215-1216. doi: 10.1001/jama.2017.11295.
Jiang J, Zhang L, Zhu Z, Li W, Li C Metacognitive training for schizophrenia: a systematic review. Shanghai Arch Psychiatry. 2015 Jun 25;27(3):149-57. doi: 10.11919/j.issn.1002-0829.215065. Review.
Kay SR, Fiszbein A, Opler LA The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76.
Liu YC, Tang CC, Hung TT, Tsai PC, Lin MF The Efficacy of Metacognitive Training for Delusions in Patients With Schizophrenia: A Meta-Analysis of Randomized Controlled Trials Informs Evidence-Based Practice. Worldviews Evid Based Nurs. 2018 Apr;15(2):130-139. doi: 10.1111/wvn.12282. Epub 2018 Feb 28. Review.
Lysaker PH, Pattison ML, Leonhardt BL, Phelps S, Vohs JL Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry. 2018 Feb;17(1):12-23. doi: 10.1002/wps.20508.
Lysaker PH, Roe D, Yanos PT Toward understanding the insight paradox: internalized stigma moderates the association between insight and social functioning, hope, and self-esteem among people with schizophrenia spectrum disorders. Schizophr Bull. 2007 Jan;33(1):192-9. Epub 2006 Aug 7.
Moritz S, Woodward T S Metacognitive Training for schizophrenia patients (MCT): A pilot study on feasibility, treatment adherence, and subjective efficacy. German Journal of Psychiatry. 2007;10(3):69-78.
Nair A, Palmer EC, Aleman A, David AS Relationship between cognition, clinical and cognitive insight in psychotic disorders: a review and meta-analysis. Schizophr Res. 2014 Jan;152(1):191-200. doi: 10.1016/j.schres.2013.11.033. Epub 2013 Dec 16. Review.
Peralta V, Cuesta MJ Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res. 1994 Jul;53(1):31-40.
Philipp R, Kriston L, Lanio J, Kühne F, Härter M, Moritz S, Meister R Effectiveness of metacognitive interventions for mental disorders in adults-A systematic review and meta-analysis (METACOG). Clin Psychol Psychother. 2019 Mar;26(2):227-240. doi: 10.1002/cpp.2345. Epub 2018 Dec 16.
Pijnenborg GH, Timmerman ME, Derks EM, Fleischhacker WW, Kahn RS, Aleman A Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST). Eur Neuropsychopharmacol. 2015 Jun;25(6):808-16. doi: 10.1016/j.euroneuro.2015.02.012. Epub 2015 Apr 20.
Pijnenborg GH, van Donkersgoed RJ, David AS, Aleman A Changes in insight during treatment for psychotic disorders: a meta-analysis. Schizophr Res. 2013 Mar;144(1-3):109-17. doi: 10.1016/j.schres.2012.11.018. Epub 2013 Jan 8. Review.
Reitan R Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills. 1958;8(3):271-6
Restifo K, Harkavy-Friedman JM, Shrout PE Suicidal behavior in schizophrenia: a test of the demoralization hypothesis. J Nerv Ment Dis. 2009 Mar;197(3):147-53. doi: 10.1097/NMD.0b013e318199f452.
Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res. 2012 May;137(1-3):246-50. doi: 10.1016/j.schres.2012.01.031. Epub 2012 Feb 21.
Wechsler D The Wechsler Adult Intelligence Scale-Revised. New York: The Psychological Corporation; 1981.
Wells A, Purdon C Metacognition and cognitive-behaviour therapy: A special issue. Clin Psychol Psychoter. 1999;6(2):71-2.
World Health Organization (WHO) WHO Disability Assessment Schedule 2.0 (WHODAS 2.0). 2010 [Available from: http://www.who.int/classifications/icf/whodasii/en/]. Accessed 22 May 2019.
Does Metacognitive Training Improve Insight and Clinical Outcomes in Schizophrenia?
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.